Colin Bristow
Stock Analyst at UBS
(1.89)
# 3,212
Out of 5,058 analysts
105
Total ratings
37.1%
Success rate
-8.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $6.88 | +45.35% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $435.52 | +25.37% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $127.18 | -11.94% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $76.69 | +4.32% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $2.94 | +70.07% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.63 | -38.65% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $23.69 | -28.24% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $343.99 | -7.26% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.66 | +140.96% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $25.45 | +10.02% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $96.43 | +24.44% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $168.83 | +19.65% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.84 | +769.57% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $725.34 | +51.52% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $17.44 | +857.57% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $1,030.05 | -59.23% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $8.50 | -76.47% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.28 | +689.47% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $233.87 | -37.57% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $47.06 | +59.37% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.48 | +948.39% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.62 | +94.81% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $6.88
Upside: +45.35%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $435.52
Upside: +25.37%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $127.18
Upside: -11.94%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $76.69
Upside: +4.32%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $2.94
Upside: +70.07%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.63
Upside: -38.65%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $23.69
Upside: -28.24%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $343.99
Upside: -7.26%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.66
Upside: +140.96%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.45
Upside: +10.02%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $96.43
Upside: +24.44%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $168.83
Upside: +19.65%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.84
Upside: +769.57%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $725.34
Upside: +51.52%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $17.44
Upside: +857.57%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $1,030.05
Upside: -59.23%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $8.50
Upside: -76.47%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.28
Upside: +689.47%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $233.87
Upside: -37.57%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $47.06
Upside: +59.37%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.48
Upside: +948.39%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $4.62
Upside: +94.81%